PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Saint Francis Health System, Tulsa, OK, USA. edwardhabraham@gmail.com.\', \'Kansas City Urology Care, Kansas City, KS, USA. edwardhabraham@gmail.com.\', \'Department of Molecular and Cell Biology, Harvard University, Cambridge, MA, USA.\', \'ATP Therapeutics, LLC, Cambridge, MA, USA.\', \'Horizon Medical Services, Tamarac, FL, USA.\', \'St. John Medical Center, Tulsa, OK, USA.\', \'University of Arkansas for Medical Sciences, Little Rock, AR, USA.\', \'Saint Francis Health System, Tulsa, OK, USA.\', \', Boston, MA, USA.\', \'Kansas City Urology Care, Kansas City, KS, USA.\', \'Bayer GU Oncology, St. Louis, MO, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s11302-021-09771-0
?:doi
?:hasPublicationType
?:journal
  • Purinergic signalling
is ?:pmid of
?:pmid
?:pmid
  • 33970408
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.104
?:rankingScore_hIndex
  • 48
?:title
  • Cystic fibrosis improves COVID-19 survival and provides clues for treatment of SARS-CoV-2.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33970408>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33970408>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all